MedPath

江苏奥赛康药业有限公司

Ownership
-
Established
2003-01-14
Employees
-
Market Cap
-
Website
https://www.ask-pharm.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

116

NMPA:116

Drug Approvals

Trifluridine and Tipiracil Hydrochloride Tablets

Product Name
曲氟尿苷替匹嘧啶片
Approval Number
国药准字H20253172
Approval Date
Jan 14, 2025
NMPA

Limertinib Tablets

Product Name
奥壹新
Approval Number
国药准字H20250004
Approval Date
Jan 14, 2025
NMPA

Trifluridine and Tipiracil Hydrochloride Tablets

Product Name
曲氟尿苷替匹嘧啶片
Approval Number
国药准字H20253171
Approval Date
Jan 14, 2025
NMPA

Neratinib Maleate Tablets

Product Name
马来酸奈拉替尼片
Approval Number
国药准字H20249180
Approval Date
Oct 22, 2024
NMPA

Fosaprepitant Dimeglumine for Injection

Product Name
注射用福沙匹坦双葡甲胺
Approval Number
国药准字H20244156
Approval Date
Jun 25, 2024
NMPA

Isavuconazonium Sulfate for Injection

Product Name
注射用硫酸艾沙康唑
Approval Number
国药准字H20243631
Approval Date
Apr 30, 2024
NMPA

Toremifene Citrate Tablets

Product Name
枸橼酸托瑞米芬片
Approval Number
国药准字H20243050
Approval Date
Jan 16, 2024
NMPA

Eltrombopag Olamine Tablets

Product Name
艾曲泊帕乙醇胺片
Approval Number
国药准字H20243005
Approval Date
Jan 9, 2024
NMPA

Dexlansoprazole for Injection

Product Name
注射用右兰索拉唑
Approval Number
国药准字H20240001
Approval Date
Jan 9, 2024
NMPA

Saxagliptin Tablets

Product Name
沙格列汀片
Approval Number
国药准字H20193009
Approval Date
Dec 25, 2023
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 12
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.